All In MedTech

Device Trial Radar · NCT06418880

Automated Insulin Delivery for Inpatients With Dysglycemia

Automated Insulin Delivery for Inpatients With Dysglycemia (AIDING) Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Jan 22, 2025

Primary completion

Oct 31, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
May 17, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the efficacy and safety of AID versus multiple daily insulin injections (MDI) + CGM in the inpatient setting * To determine differences in CGM-derived metrics between AID and MDI plus CGM in the hospital and explore differences in treatment effect according to individual characteristics. Participants will be: * Randomized to AID + remote CGM (intervention) or multiple daily insulin injections (MDI) + CGM (control group) * Followed for a total of 10 days or until hospital discharge (if less than 10 days).

Conditions

  • Type 1 Diabetes
  • Type 2 Diabetes

Interventions

  • AID system with Remote Real-Time CGMDevice

    The Omnipod 5 AID System is comprised of two components: * Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology) * Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses.

  • Standard of Care Insulin Therapy + CGMCombination product

    This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days). Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Time spent in glucose target rangeTime frame: Up to 10 days (or hospital discharge if before 10 days)
  2. Safety: Time spent below the target glucose rangeTime frame: Up to 10 days (or hospital discharge if before 10 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University School of Medicine

    Stanford, California

  • Grady Health System (non-CRN)

    Atlanta, Georgia

  • University of Virginia School of Medicine

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.